What is NIKA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.37B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NIKA?

P/E (TTM) is n/a and 52-week range is $0.20 to $0.97 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NIKA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

Where is Nika Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Henderson, Nevada, US, 1.05B shares outstanding, ISIN US1513411041 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Nika Pharmaceuticals Inc

$NIKA

Health Care · Pharmaceuticals

Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Nika Pharmaceuticals, Inc. engages in the development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. The company is headquartered in Henderson, Nevada and currently employs 0 full-time employees. The company went IPO on 2024-01-24. The company has the exclusive rights agreement for the production and distribution of two dietary supplements, namely Carotilen and Physiolong. Carotilen is a dietary supplement in the form of soft gelatin capsules that improves and regulates the metabolism of the epithelial cells and protects them from degenerative alterations. Physiolong is a dietary food supplement in the form of hard gelatin capsules, which serves as a general stimulant for those in a period of convalescence, as well as in situations of high mental and physical loads. The company has an exclusive rights agreement for the production and distribution of Thymus Nuclear Glycoprotein (TNG). The company also has the rights agreement for the production and sale of an additional six dietary supplements, such as Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C, and Silymaron.

Website

www.nikapharmaceuticals.com/

IPO

2024-01-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)